keyword
MENU ▼
Read by QxMD icon Read
search

anti-tnf

keyword
https://www.readbyqxmd.com/read/29224199/paradoxical-psoriasiform-reactions-of-anti-tumour-necrosis-factor-therapy-in-inflammatory-bowel-disease-patients
#1
Faseeha C Peer, Andrew Miller, Paul Pavli, Kavitha Subramaniam
Anti-tumour necrosis factor (TNF) agents have demonstrated efficacy in inflammatory bowel disease (IBD). Cutaneous reactions such as new onset psoriasis or psoriasiform-like reactions are among the most common adverse reactions. We retrospectively identified cases of anti-TNF-induced psoriasis or psoriasiform manifestations in IBD patients at a tertiary centre in Australia. A total of 10 (six females) of 270 (3.7%) IBD patients treated with anti-TNF therapy developed drug-induced psoriatic or psoriasiform-like reactions: five patients were treated with infliximab and five with adalimumab; nine had Crohn disease...
December 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29223453/hbv-reactivation-in-rheumatic-diseases-patients-under-therapy-a-meta-analysis
#2
REVIEW
Mohsen Moghoofei, Shayan Mostafaei, Amir Ashraf-Ganjouei, Hoda Kavosi, Mahdi Mahmoudi
BACKGROUND: Hepatitis B is one of the most common infectious diseases worldwide. In patients undergoing immunosuppressive therapy such as rheumatic diseases, reactivation of Hepatitis B virus (HBV) is considered clinically important. This systematic review and meta-analysis were performed to determine the prevalence rate of HBV reactivation in rheumatic patients from different parts of the world. It is worth mentioning that the aim of the current study was to report the prevalence of HBV with the application of meta-analysis...
December 6, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/29220430/postoperative-outcomes-in-ustekinumab-treated-patients-undergoing-abdominal-operations-for-crohn-s-disease
#3
Amy L Lightner, Nicholas P McKenna, Chung Sang Tse, Neil Hyman, Radhika Smith, Gayane Ovsepyan, Phillip Fleshner, Kristen Crowell, Walter Koltun, Marc Ferrante, Andre D'Hoore, Nathalie Lauwers, Bram Verstockt, Antonino Spinelli, Francesca DiCandido, Laura E Raffals, Kellie L Mathis, Edward V Loftus
Introduction: Ustekinumab, a monoclonal antibody targeting interleukins-12 and -23 is used to treat adults with Crohn's disease (CD). We determined the 30-day postoperative infectious complication rate among CD patients who received ustekinumab within 12 weeks prior to an abdominal operation as compared to patients who received anti-tumor necrosis factor (TNF) agents. Methods: A retrospective chart review of adults with CD who underwent an abdominal operation between 1/1/2015 and 5/1/2017 was performed across six sites...
December 6, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29218326/study-protocol-a-multi-centre-double-blind-randomised-placebo-controlled-parallel-group-phase-ii-trial-ridd-to-determine-the-efficacy-of-intra-nodular-injection-of-anti-tnf-to-control-disease-progression-in-early-dupuytren-s-disease-with-an-embedded-dose-response
#4
Jagdeep Nanchahal, Catherine Ball, Jennifer Swettenham, Susan Dutton, Vicki Barber, Joanna Black, Bethan Copsey, Melina Dritsaki, Peter Taylor, Alastair Gray, Marc Feldmann, Sarah Lamb
Dupuytren's disease is a common fibrotic condition of the hand affecting 4% of the population and causes the fingers to curl irreversibly into the palm. It has a strong familial tendency, there is no approved treatment for early stage disease, and patients with established digital contractures are most commonly treated by surgery. This is associated with prolonged recovery, and less invasive techniques have high recurrence rates.The myofibroblasts, the cells responsible for the excessive matrix deposition and contraction, are aggregated in nodules...
2017: Wellcome Open Research
https://www.readbyqxmd.com/read/29215627/a-pharmacokinetic-rationale-for-proactive-therapeutic-drug-monitoring-of-anti-tnf-drugs
#5
Andrew R Reinink
No abstract text is available yet for this article.
December 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29215183/use-of-biological-drugs-in-patients-with-psoriasis-and-psoriatic-arthritis-in-italy-results-from-the-psong-survey
#6
Maria C Potenza, Ketty Peris, Enzo Berardesca, Luca Bianchi, Antonio Richetta, Nicoletta Bernardini, Clara De Simone, Miriam Teoli, Arianna Zangrilli, Sara D'epiro, Diego Orsini, Alessandra Narcisi, Sergio Chimenti, Antonio Costanzo
This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression...
December 7, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/29214394/serious-adverse-events-associated-with-anti-tumor-necrosis-factor-alpha-agents-in-pediatric-onset-inflammatory-bowel-disease-and-juvenile-idiopathic-arthritis-in-a-real-life-setting
#7
Serena Pastore, Samuele Naviglio, Arianna Canuto, Loredana Lepore, Stefano Martelossi, Alessandro Ventura, Andrea Taddio
OBJECTIVES: Anti-tumor necrosis factor alpha (anti-TNF-α) agents are generally well tolerated, yet they can be associated with serious adverse events (SAEs) in a minority of patients. We examined the incidence of SAEs in a pediatric referral center for chronic rheumatologic and gastroenterological inflammatory disorders. METHODS: Retrospective analysis of SAEs occurring during treatment with anti-TNF-α agents in patients with juvenile idiopathic arthritis (JIA) (n = 78)  or pediatric-onset inflammatory bowel disease (IBD) (n = 105) seen at the Institute for Maternal and Child Health IRCCS "Burlo Garofolo" in Trieste, Italy, between June 2001 and February 2016...
December 6, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29213024/-a-refractory-case-of-ulcerative-colitis-developed-after-the-cessation-smoking-achieved-clinical-and-endoscopic-remission-after-resuming-smoking
#8
Tetsuro Hamamoto, Masashi Ohtani, Eiji Matsumoto, Tatsuaki Hori, Ichiro Tsuruhara, Kazuo Yashima, Hajime Isomoto
A 42-year-old man, who had stopped smoking almost one year ago, visited our hospital for hematochezia. He was diagnosed as having ulcerative colitis and was prescribed 5-amino salicylic acid and corticosteroids, which led to the remission of his disease. However, the disease relapsed after sufficient continuous corticosteroids administration and persisted despite 5-amino salicylic acid administration and intensive treatment with corticosteroids, immune modulators, leukocyte apheresis, and anti-TNF-α antibodies...
2017: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/29212102/-conservative-treatment-of-an-aseptic-abscess-syndrome-with-splenic-abscesses-in-crohn-s-disease
#9
Thomas Göbel, Jutta Rauen-Vossloh, Hubert Georg Hotz, Andree Boldt, Andreas Erhardt
A 24-year old woman with a history of Crohn's disease developed bloody diarrhea and multiple abdominal abscesses, daily fever, leukocytosis, and elevated CRP several months after her immunosuppressive therapy with azathioprine was stopped. Recurrent abscess punctures did not detect any pathogenic germs and neither clinical nor serological response was achieved by administration of different antimicrobial therapies. Additionally, new splenic abscesses arose despite ongoing therapy. Under the suspicion of the rare aseptic abscess syndrome, representing an auto-inflammatory, extra-intestinal manifestation of Crohn's disease, the antimicrobial therapy was stopped and an intravenous therapy with prednisolone was initiated...
December 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29212085/the-impact-of-anti-tnf-therapy-on-cd4-and-cd8-cell-subsets-in-ankylosing-spondylitis
#10
Sonja Dulic, Zsofia Vasarhelyi, Anna Bajnok, Balazs Szalay, Gergely Toldi, Laszlo Kovacs, Attila Balog
OBJECTIVES: Ankylosing spondylitis (AS) is a chronic, progressive immune-mediated inflammatory disease, driven primarily by Th1 and Th17 cells. Anti-TNF therapies are successfully used in AS to achieve and maintain remission. However, their influence on the composition of T-cell subsets is not clear. We aimed to characterize the changes in the T-cell repertoire after a long-term anti-TNF treatment in AS patients. METHODS: Twenty-two AS patients under long-term anti-TNF therapy were evaluated (15 anti-TNF responders and 7 nonresponders)...
December 6, 2017: Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology
https://www.readbyqxmd.com/read/29210919/the-role-of-combination-therapy-in-pediatric-inflammatory-bowel-disease-ibd-a-clinical-report-from-the-north-american-society-for-pediatric-gastroenterology-hepatology-and-nutrition
#11
Andrew S Day, Ajay S Gulati, Nishaben Patel, Brendan Boyle, K T Park, Shehzad A Saeed
The treatment goal for children suffering from inflammatory bowel disease (IBD) has been evolving with biologic therapies like anti-TNF agents assuming a more central role in treatment of more aggressive and extensive phenotype. Earlier introduction of anti-TNF agents have shown to be more effective and may even alter the natural history of IBD. However, development of anti-drug antibodies (ADA) limits long term usage and leads to dose adjustment in almost half of patients treated with these medications. One of the strategies to minimize the development of ADA has been concomitant use of immunomodulator (IM) medications, resulting in fewer infusion reactions and sustained trough levels, potentially lowering the need for dose adjustments...
November 28, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29209921/fourteen-year-anti-tnf-therapy-in-crohn-s-disease-patients-clinical-characteristics-and-predictive-factors
#12
Aisaku Osamura, Yasuo Suzuki
BACKGROUND: Crohn's disease (CD) is an intractable disease that requires long-term treatment. Tumor necrosis factor (TNF) inhibitors have strong efficacy and are widely used for CD treatment. However, a loss of response is one of the issues in long-term TNF therapy. To identify the factors affecting the efficacy of long-term CD treatment with TNF inhibitors, we conducted a retrospective study of treatment outcomes and clinical factors using clinical data over a 14-year period. METHODS: Clinical characteristics and factors for surgery, hospitalization, and TNF inhibitor treatment discontinuation were examined in 219 biologic-naïve patients who were treated with TNF inhibitors at our hospital before October 2014...
December 5, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29209104/t-cell-subsets-in-rheumatoid-arthritis-patients-on-long-term-anti-tnf-or-il-6-receptor-blocker-therapy
#13
Sonja Dulic, Zsófia Vásárhelyi, Florentina Sava, László Berta, Balázs Szalay, Gergely Toldi, László Kovács, Attila Balog
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. Here, we prospectively measured the percentages of 15 circulating T-cell subtypes using flow cytometry. We obtained transversal and longitudinal data in 30 anti-TNF responders, 19 secondary anti-TNF nonresponders, and 43 IL-6R antagonist responders, before, 8 weeks and at least 6 months after biological therapy. Untreated RA patients and healthy controls were also included. The important findings are the following: (1) the proportion of regulatory T-cells (Tregs) which are decreased in untreated RA patients becomes normal in all long-term-treated groups; (2) in anti-TNF responders as well as in nonresponders, the frequencies of naïve CD4+ and CD8+ cells are lower, whereas those of proinflammatory Th1, Th2, and Th17 cells and HLA-DR+-activated cells are higher than those in untreated RA or healthy controls; (3) in IL-6R responders, Th1 proportion is decreased, while that of Th2 and Th17 is increased as compared to that in anti-TNF-treated patients and controls; (4) pending confirmation, a CD4CD69 ratio < 2...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/29205926/a-retrospective-review-of-the-persistence-on-bdmards-prescribed-for-the-treatment-of-rheumatoid-arthritis-in-the-australian-population
#14
Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett, Peter Button
AIM: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage. METHOD: RA patients, from the 10% Australian Medicare random sample, aged ≥18 for whom bDMARDs were dispensed were included. Individual sub-cutaneous (SC) anti-tumor necrosis factor-α (anti-TNFα) agents were combined as they were equivalent...
December 5, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29205406/systematic-review-and-network-meta-analysis-first-and-second-line-pharmacotherapy-for-moderate-severe-ulcerative-colitis
#15
S Singh, M Fumery, W J Sandborn, M H Murad
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach...
December 4, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29204064/vaccinations-in-immunosuppressive-dependent-pediatric-inflammatory-bowel-disease
#16
Huyen-Tran Nguyen, Phillip Minar, Kimberly Jackson, Patricia C Fulkerson
AIM: To determine the vaccination rates in pediatric immunosuppression-dependent inflammatory bowel disease (IBD) and review the safety and efficacy of vaccinations in this population. METHODS: The electronic medical records from October 2009 to December 2015 of patients diagnosed with IBD at 10 years of age or younger and prescribed anti-tumor necrosis factor alpha (anti-TNF-α) therapy were reviewed for clinical history, medication history, vaccination history, and hepatitis B and varicella titers...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29202588/therapeutic-drug-monitoring-of-anti-tnf-therapy-in-children-with-inflammatory-bowel-disease
#17
Karen van Hoeve, Ilse Hoffman, Severine Vermeire
Although anti-TNF therapy has changed the scenery of pediatric inflammatory bowel diseases (IBD) immensely, there are still patients with an unfortunate outcome. Approximately one third of patients that initially respond to anti-TNF therapy will lose that response over time and need treatment optimization. Loss of response (LOR) is a big concern in IBD management and especially among pediatric patients where treatment options are more limited than in adults. In children it is even more important to sustain response with minimal toxicity...
December 5, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29200248/detection-of-anti-infliximab-antibodies-in-slovak-ibd-patients-and-its-costs-saving-effect
#18
(no author information available yet)
OBJECTIVE: Management chronic inflammatory bowel disease (IBD) patients is associated with diagnosis, targeted treatment and and individual approach. There is a group of patients which loss the response to the biologic treatment caused by insufficient levels of biologics or positive antibodies against these drugs. This study was aimed to determine the prevalence of patients with positive antibodies against the biological treatment and the costs saving probabilities of the antibodies detection during the treatment...
November 4, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/29197269/anti-tumour-necrosis-factor-%C3%AE-antibodies-and-b-cell-homeostasis-in-human-inflammatory-bowel-diseases
#19
Caterina Defendenti, Fabiola Atzeni, Sergio Malandrin, Sandro Ardizzone, Piero Luigi Almasio, Simone Saibeni, Cristina Bezzio, Simona Bollani, Raffaele Salerno, Paolo Declich, Zoe Sarno, Savino Bruno, Rossella Talotta, Piercarlo Sarzi-Puttini
BACKGROUND: The expression of CD70 on T cells is greatly enhanced by antigen-presenting cell (APC)-associated signals, such as tumour necrosis factor(TNF)-α, which is constitutionally high in patients with inflammatory bowel disease (IBD). Experimentally, the chronic activation of CD27 as a result of the constitutive expression of CD70 leads to the demise of B cells in bone marrow (BM) and the secondary lymphoid organs. The aim of this study was to assess the number and phenotype of circulating B cell in untreated IBD patients and their counterparts treated with biological anti-TNF drugs...
November 29, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29196456/deep-coverage-tissue-and-cellular-proteomics-revealed-il-1%C3%AE-can-independently-induce-the-secretion-of-tnf-associated-proteins-from-human-synoviocytes
#20
Shengquan Tang, Suyuan Deng, Jiahui Guo, Xing Chen, Wanling Zhang, Yizhi Cui, Yanzhang Luo, Ziqi Yan, Qing-Yu He, Shan Shen, Tong Wang
Synovitis is a key contributor to the inflammatory environment in osteoarthritis (OA) joints. Currently, the biological therapy of OA is not satisfactory in multiple single-target trials on anti-TNF agents, or IL-1 antagonists. Systems biological understanding of the phosphorylation state in OA synovium is warranted to direct further therapeutic strategies. Therefore, in this study, we compared the human synovial phosphoproteome of the OA with the acute joint fracture subjects. We found that OA synovium had significantly more phosphoproteins, and 82 phosphoproteins could only be specifically found in all the OA samples...
December 1, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
keyword
keyword
34737
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"